INTRODUCTION: Partial nephrectomy is the standard of care for cT1a renal masses, offering equivalent oncologic outcomes and lower renal function impairment when compared to radical nephrectomy, with excellent overall survival results. Robot-assisted partial nephrectomy (RAPN) allows to perform a precise tumor excision, simplifying the reconstruction steps of the procedure, especially in the treatment of complex or large renal tumors. Aim of this study was to summarize the available perioperative, functional, and oncological outcomes of RAPN performed for complex and/or large (cT1b) renal cell carcinoma (RCC). MATERIALS AND METHODS: We performed a nonsystematic review of the literature using a free-text protocol in the Medline database, using the terms "robot-assisted partial nephrectomy" and "robotic partial nephrectomy." Two Authors reviewed separately to select RAPN series reporting data about complex and cT1b RCC. Other significant studies cited in the reference lists of the selected papers were also evaluated. EVIDENCE SYNTHESIS: According to the currently available evidences, RAPN offers promising results in terms of perioperative, functional, and oncological outcomes for the conservative management of complex or large renal tumors, even when compared with open and laparoscopic partial nephrectomy. Robot-assisted procedure allows surgeons to treat large and challenging renal masses, even if with higher warm ischemia time, operating time, and estimated blood loss in comparison with those obtained for the treatment of smaller lesions. CONCLUSIONS: In the hands of experienced surgeons, RAPN is a safe and reproducible approach for the treatment of cT1b and more challenging renal tumors, and could represent the way to expand the indications for minimally invasive conservative approach to RCC.
INTRODUCTION: Partial nephrectomy is the standard of care for cT1a renal masses, offering equivalent oncologic outcomes and lower renal function impairment when compared to radical nephrectomy, with excellent overall survival results. Robot-assisted partial nephrectomy (RAPN) allows to perform a precise tumor excision, simplifying the reconstruction steps of the procedure, especially in the treatment of complex or large renal tumors. Aim of this study was to summarize the available perioperative, functional, and oncological outcomes of RAPN performed for complex and/or large (cT1b) renal cell carcinoma (RCC). MATERIALS AND METHODS: We performed a nonsystematic review of the literature using a free-text protocol in the Medline database, using the terms "robot-assisted partial nephrectomy" and "robotic partial nephrectomy." Two Authors reviewed separately to select RAPN series reporting data about complex and cT1b RCC. Other significant studies cited in the reference lists of the selected papers were also evaluated. EVIDENCE SYNTHESIS: According to the currently available evidences, RAPN offers promising results in terms of perioperative, functional, and oncological outcomes for the conservative management of complex or large renal tumors, even when compared with open and laparoscopic partial nephrectomy. Robot-assisted procedure allows surgeons to treat large and challenging renal masses, even if with higher warm ischemia time, operating time, and estimated blood loss in comparison with those obtained for the treatment of smaller lesions. CONCLUSIONS: In the hands of experienced surgeons, RAPN is a safe and reproducible approach for the treatment of cT1b and more challenging renal tumors, and could represent the way to expand the indications for minimally invasive conservative approach to RCC.
Authors: Hendrik Van Poppel; Luigi Da Pozzo; Walter Albrecht; Vsevolod Matveev; Aldo Bono; Andrzej Borkowski; Marc Colombel; Laurence Klotz; Eila Skinner; Thomas Keane; Sandrine Marreaud; Sandra Collette; Richard Sylvester Journal: Eur Urol Date: 2010-12-22 Impact factor: 20.096
Authors: Simon P Kim; R Houston Thompson; Stephen A Boorjian; Christopher J Weight; Leona C Han; M Hassan Murad; Nathan D Shippee; Patricia J Erwin; Brian A Costello; George K Chow; Bradley C Leibovich Journal: J Urol Date: 2012-05-14 Impact factor: 7.450
Authors: Steven C Campbell; Andrew C Novick; Arie Belldegrun; Michael L Blute; George K Chow; Ithaar H Derweesh; Martha M Faraday; Jihad H Kaouk; Raymond J Leveillee; Surena F Matin; Paul Russo; Robert G Uzzo Journal: J Urol Date: 2009-08-14 Impact factor: 7.450
Authors: Vincenzo Ficarra; Sam Bhayani; James Porter; Nicolò Buffi; Robin Lee; Andrea Cestari; Giacomo Novara; Alexander Mottrie Journal: World J Urol Date: 2012-09-11 Impact factor: 4.226
Authors: Ryan A Hankins; Annerleim Walton-Diaz; Hong Truong; Joanna Shih; Gennady Bratslavsky; Peter A Pinto; W Marston Linehan; Adam R Metwalli Journal: Int Urol Nephrol Date: 2016-08-11 Impact factor: 2.370
Authors: Dae Keun Kim; Lawrence H C Kim; Ali Abdel Raheem; Tae Young Shin; Ibrahim Alabdulaali; Young Eun Yoon; Woong Kyu Han; Koon Ho Rha Journal: PLoS One Date: 2016-03-17 Impact factor: 3.240
Authors: Girdhar S Bora; Ravimohan S Mavuduru; Aditya P Sharma; Sudheer K Devana; Nandita Kakkar; Anupam Lal; Shrawan K Singh; Arup K Mandal Journal: Indian J Urol Date: 2017 Jul-Sep
Authors: Pietro Piazza; Artur de Oliveira Paludo; Stefano Puliatti; Giuseppe Rosiello; Rui Farinha; Marco Amato; Riccardo Schiavina; Eugenio Brunocilla; Camille Berquin; Ruben De Groote; Louis Thielman; Alexandre Mottrie; Geert De Naeyer Journal: CEN Case Rep Date: 2021-03-08